Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

77.97 +0.74 (+0.96%)
Official Closing Price Updated: 7:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,262,476
Open 77.55
Bid (Size) 77.94 (3)
Ask (Size) 78.03 (4)
Prev. Close 77.23
Today's Range 77.42 - 79.18
52wk Range 73.31 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 4.16%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals
MERCK & CO. (NYSE:MRK) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector. 
Via Chartmill

Performance

YTD
-21.4%
-21.4%
1 Month
+0.2%
+0.2%
3 Month
-6.4%
-6.4%
6 Month
-19.2%
-19.2%
1 Year
-40.5%
-40.5%

More News

Read More
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From Daiichi Sankyo
Via Business Wire
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
From Merck & Co., Inc.
Via Business Wire
Decoding Merck & Co's Options Activity: What's the Big Picture?
Via Benzinga
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Via Benzinga
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
Via Benzinga
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
Via Benzinga
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
From Merck & Co., Inc.
Via Business Wire
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
From Merck & Co., Inc.
Via Business Wire
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
Via Benzinga
FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors
Via Benzinga
Exposures Product Safety
3 Absurdly Cheap Stocks Trading Near Their 52-Week Lows
Via The Motley Fool
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
Via Benzinga
Topics Stocks
Exposures US Equities
Assessing Merck & Co: Insights From 4 Financial Analysts
Via Benzinga
Top S&P500 movers in Tuesday's session
Via Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday.
Via Chartmill
These S&P500 stocks are gapping in today's session
Via Chartmill
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
From Merck & Co., Inc.
Via Business Wire
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Via Chartmill
Topics Government World Trade
Exposures Political Tariff
Dow Jones Adds 1,000 Points, Breaks 200-Day Moving Average For First Time Since April 2 Tariff Shock
Via Benzinga
Topics Stocks
Exposures US Equities
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order
Via Stocktwits
Topics Government
Exposures Political
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 77.97
When was Merck & Co last traded?
The last trade of Merck & Co was at 05/20/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 197.37B
How many shares of Merck & Co are outstanding?
Merck & Co has 197B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.